nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—NR3C1—urine—kidney cancer	0.0249	0.153	CbGeAlD
Fluocinonide—Leukoderma—Pazopanib—kidney cancer	0.0245	0.0351	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Everolimus—kidney cancer	0.0241	0.0344	CcSEcCtD
Fluocinonide—SMO—cortex of kidney—kidney cancer	0.0238	0.146	CbGeAlD
Fluocinonide—Dermatitis acneiform—Erlotinib—kidney cancer	0.0232	0.0332	CcSEcCtD
Fluocinonide—SMO—cardiac atrium—kidney cancer	0.0226	0.139	CbGeAlD
Fluocinonide—Hypertrichosis—Everolimus—kidney cancer	0.0216	0.031	CcSEcCtD
Fluocinonide—Folliculitis—Temsirolimus—kidney cancer	0.0176	0.0252	CcSEcCtD
Fluocinonide—Leukoderma—Sunitinib—kidney cancer	0.0162	0.0231	CcSEcCtD
Fluocinonide—SERPINA6—nephron tubule—kidney cancer	0.0153	0.0942	CbGeAlD
Fluocinonide—SERPINA6—renal system—kidney cancer	0.0139	0.0856	CbGeAlD
Fluocinonide—SERPINA6—kidney—kidney cancer	0.0134	0.0828	CbGeAlD
Fluocinonide—SERPINA6—cortex of kidney—kidney cancer	0.0131	0.0806	CbGeAlD
Fluocinonide—Folliculitis—Everolimus—kidney cancer	0.0131	0.0187	CcSEcCtD
Fluocinonide—Folliculitis—Erlotinib—kidney cancer	0.0126	0.0181	CcSEcCtD
Fluocinonide—Folliculitis—Sorafenib—kidney cancer	0.0114	0.0162	CcSEcCtD
Fluocinonide—Eruption—Dactinomycin—kidney cancer	0.0106	0.0151	CcSEcCtD
Fluocinonide—Amcinonide—ANXA1—kidney cancer	0.0105	0.443	CrCbGaD
Fluocinonide—Folliculitis—Dactinomycin—kidney cancer	0.0103	0.0148	CcSEcCtD
Fluocinonide—Skin exfoliation—Pazopanib—kidney cancer	0.00995	0.0142	CcSEcCtD
Fluocinonide—Swelling—Temsirolimus—kidney cancer	0.0091	0.013	CcSEcCtD
Fluocinonide—Eruption—Gemcitabine—kidney cancer	0.00896	0.0128	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—kidney cancer	0.00831	0.0119	CcSEcCtD
Fluocinonide—Skin exfoliation—Everolimus—kidney cancer	0.00785	0.0112	CcSEcCtD
Fluocinonide—Skin exfoliation—Erlotinib—kidney cancer	0.00758	0.0108	CcSEcCtD
Fluocinonide—Dry skin—Temsirolimus—kidney cancer	0.00736	0.0105	CcSEcCtD
Fluocinonide—Folliculitis—Paclitaxel—kidney cancer	0.00734	0.0105	CcSEcCtD
Fluocinonide—Dry skin—Pazopanib—kidney cancer	0.00693	0.00992	CcSEcCtD
Fluocinonide—Skin exfoliation—Sorafenib—kidney cancer	0.00682	0.00975	CcSEcCtD
Fluocinonide—Nasopharyngitis—Pazopanib—kidney cancer	0.00676	0.00967	CcSEcCtD
Fluocinonide—NR3C1—nephron tubule—kidney cancer	0.0067	0.0413	CbGeAlD
Fluocinonide—Skin exfoliation—Sunitinib—kidney cancer	0.00656	0.00938	CcSEcCtD
Fluocinonide—Nasal congestion—Everolimus—kidney cancer	0.00655	0.00938	CcSEcCtD
Fluocinonide—Hyperglycaemia—Temsirolimus—kidney cancer	0.00626	0.00895	CcSEcCtD
Fluocinonide—NR3C1—renal system—kidney cancer	0.00609	0.0375	CbGeAlD
Fluocinonide—NR3C1—kidney—kidney cancer	0.00589	0.0363	CbGeAlD
Fluocinonide—Leukoderma—Doxorubicin—kidney cancer	0.00574	0.00822	CcSEcCtD
Fluocinonide—NR3C1—cortex of kidney—kidney cancer	0.00573	0.0353	CbGeAlD
Fluocinonide—Nasal congestion—Sunitinib—kidney cancer	0.00547	0.00783	CcSEcCtD
Fluocinonide—Dry skin—Everolimus—kidney cancer	0.00547	0.00783	CcSEcCtD
Fluocinonide—NR3C1—gonad—kidney cancer	0.00546	0.0336	CbGeAlD
Fluocinonide—NR3C1—cardiac atrium—kidney cancer	0.00545	0.0336	CbGeAlD
Fluocinonide—Nasopharyngitis—Everolimus—kidney cancer	0.00534	0.00764	CcSEcCtD
Fluocinonide—Dry skin—Erlotinib—kidney cancer	0.00528	0.00755	CcSEcCtD
Fluocinonide—Skin exfoliation—Gemcitabine—kidney cancer	0.00526	0.00753	CcSEcCtD
Fluocinonide—Immune system disorder—Temsirolimus—kidney cancer	0.00502	0.00717	CcSEcCtD
Fluocinonide—Erythema—Temsirolimus—kidney cancer	0.00483	0.00691	CcSEcCtD
Fluocinonide—Dry skin—Sorafenib—kidney cancer	0.00475	0.0068	CcSEcCtD
Fluocinonide—Hyperglycaemia—Everolimus—kidney cancer	0.00466	0.00666	CcSEcCtD
Fluocinonide—Nasopharyngitis—Sorafenib—kidney cancer	0.00463	0.00663	CcSEcCtD
Fluocinonide—Dry skin—Sunitinib—kidney cancer	0.00457	0.00654	CcSEcCtD
Fluocinonide—Erythema—Pazopanib—kidney cancer	0.00455	0.00651	CcSEcCtD
Fluocinonide—Nasopharyngitis—Sunitinib—kidney cancer	0.00446	0.00638	CcSEcCtD
Fluocinonide—Skin exfoliation—Paclitaxel—kidney cancer	0.00441	0.0063	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.00409	0.00585	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—kidney cancer	0.00397	0.00568	CcSEcCtD
Fluocinonide—Infection—Temsirolimus—kidney cancer	0.00392	0.00561	CcSEcCtD
Fluocinonide—Hyperglycaemia—Sunitinib—kidney cancer	0.00389	0.00556	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—kidney cancer	0.00388	0.00556	CcSEcCtD
Fluocinonide—Nervous system disorder—Temsirolimus—kidney cancer	0.00387	0.00553	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00385	0.00551	CcSEcCtD
Fluocinonide—Skin disorder—Temsirolimus—kidney cancer	0.00383	0.00548	CcSEcCtD
Fluocinonide—Swelling—Paclitaxel—kidney cancer	0.0038	0.00543	CcSEcCtD
Fluocinonide—Immune system disorder—Everolimus—kidney cancer	0.00373	0.00534	CcSEcCtD
Fluocinonide—Infection—Pazopanib—kidney cancer	0.00369	0.00528	CcSEcCtD
Fluocinonide—Nasal congestion—Paclitaxel—kidney cancer	0.00368	0.00526	CcSEcCtD
Fluocinonide—Nervous system disorder—Pazopanib—kidney cancer	0.00365	0.00521	CcSEcCtD
Fluocinonide—Skin exfoliation—Capecitabine—kidney cancer	0.00362	0.00517	CcSEcCtD
Fluocinonide—Skin disorder—Pazopanib—kidney cancer	0.00361	0.00516	CcSEcCtD
Fluocinonide—Erythema—Everolimus—kidney cancer	0.0036	0.00514	CcSEcCtD
Fluocinonide—Erythema—Erlotinib—kidney cancer	0.00347	0.00496	CcSEcCtD
Fluocinonide—SMO—Hedgehog 'off' state—PSMD7—kidney cancer	0.00338	0.0294	CbGpPWpGaD
Fluocinonide—Pain—Temsirolimus—kidney cancer	0.00337	0.00483	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—kidney cancer	0.00336	0.0293	CbGpPWpGaD
Fluocinonide—Dexamethasone—ANXA1—kidney cancer	0.00329	0.139	CrCbGaD
Fluocinonide—Immune system disorder—Sorafenib—kidney cancer	0.00324	0.00463	CcSEcCtD
Fluocinonide—Pain—Pazopanib—kidney cancer	0.00318	0.00455	CcSEcCtD
Fluocinonide—Erythema—Sorafenib—kidney cancer	0.00312	0.00446	CcSEcCtD
Fluocinonide—Hyperglycaemia—Gemcitabine—kidney cancer	0.00312	0.00446	CcSEcCtD
Fluocinonide—Swelling—Capecitabine—kidney cancer	0.00312	0.00446	CcSEcCtD
Fluocinonide—Immune system disorder—Sunitinib—kidney cancer	0.00312	0.00446	CcSEcCtD
Fluocinonide—Dry skin—Paclitaxel—kidney cancer	0.00307	0.00439	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00304	0.00435	CcSEcCtD
Fluocinonide—SMO—Signaling by Hedgehog—PSMD7—kidney cancer	0.00302	0.0263	CbGpPWpGaD
Fluocinonide—Glycosuria—Doxorubicin—kidney cancer	0.00301	0.00431	CcSEcCtD
Fluocinonide—Erythema—Sunitinib—kidney cancer	0.003	0.0043	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—HNF1A—kidney cancer	0.003	0.0261	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Paclitaxel—kidney cancer	0.003	0.00429	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.00293	0.0042	CcSEcCtD
Fluocinonide—Infection—Everolimus—kidney cancer	0.00292	0.00417	CcSEcCtD
Fluocinonide—Hypersensitivity—Temsirolimus—kidney cancer	0.00291	0.00416	CcSEcCtD
Fluocinonide—Nervous system disorder—Everolimus—kidney cancer	0.00288	0.00412	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—FOSL2—kidney cancer	0.00286	0.0249	CbGpPWpGaD
Fluocinonide—Skin disorder—Everolimus—kidney cancer	0.00285	0.00408	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—kidney cancer	0.00284	0.00407	CcSEcCtD
Fluocinonide—Infection—Erlotinib—kidney cancer	0.00281	0.00402	CcSEcCtD
Fluocinonide—Pruritus—Temsirolimus—kidney cancer	0.00279	0.00399	CcSEcCtD
Fluocinonide—Nervous system disorder—Erlotinib—kidney cancer	0.00278	0.00397	CcSEcCtD
Fluocinonide—Skin disorder—Erlotinib—kidney cancer	0.00275	0.00393	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—EGR1—kidney cancer	0.00267	0.0232	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.00264	0.00378	CcSEcCtD
Fluocinonide—Pruritus—Pazopanib—kidney cancer	0.00263	0.00376	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.00262	0.0228	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.00262	0.0228	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Paclitaxel—kidney cancer	0.00261	0.00374	CcSEcCtD
Fluocinonide—Dizziness—Temsirolimus—kidney cancer	0.00261	0.00373	CcSEcCtD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—PIK3CA—kidney cancer	0.00259	0.0226	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.00254	0.00363	CcSEcCtD
Fluocinonide—Infection—Sorafenib—kidney cancer	0.00253	0.00362	CcSEcCtD
Fluocinonide—Dry skin—Capecitabine—kidney cancer	0.00252	0.00361	CcSEcCtD
Fluocinonide—Pain—Vinblastine—kidney cancer	0.00252	0.0036	CcSEcCtD
Fluocinonide—Pain—Everolimus—kidney cancer	0.00251	0.00359	CcSEcCtD
Fluocinonide—Immune system disorder—Gemcitabine—kidney cancer	0.0025	0.00358	CcSEcCtD
Fluocinonide—Nervous system disorder—Sorafenib—kidney cancer	0.0025	0.00357	CcSEcCtD
Fluocinonide—Rash—Temsirolimus—kidney cancer	0.00249	0.00356	CcSEcCtD
Fluocinonide—Dermatitis—Temsirolimus—kidney cancer	0.00249	0.00356	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.00248	0.0216	CbGpPWpGaD
Fluocinonide—Skin disorder—Sorafenib—kidney cancer	0.00247	0.00354	CcSEcCtD
Fluocinonide—Headache—Temsirolimus—kidney cancer	0.00247	0.00354	CcSEcCtD
Fluocinonide—Nasopharyngitis—Capecitabine—kidney cancer	0.00246	0.00352	CcSEcCtD
Fluocinonide—Dizziness—Pazopanib—kidney cancer	0.00246	0.00352	CcSEcCtD
Fluocinonide—Infection—Sunitinib—kidney cancer	0.00244	0.00348	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—TFE3—kidney cancer	0.00243	0.0212	CbGpPWpGaD
Fluocinonide—Pain—Erlotinib—kidney cancer	0.00242	0.00346	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—kidney cancer	0.00241	0.00345	CcSEcCtD
Fluocinonide—Erythema—Gemcitabine—kidney cancer	0.00241	0.00345	CcSEcCtD
Fluocinonide—Nervous system disorder—Sunitinib—kidney cancer	0.0024	0.00344	CcSEcCtD
Fluocinonide—Skin disorder—Sunitinib—kidney cancer	0.00238	0.00341	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—CER1—kidney cancer	0.00234	0.0204	CbGpPWpGaD
Fluocinonide—Rash—Pazopanib—kidney cancer	0.00234	0.00335	CcSEcCtD
Fluocinonide—Dermatitis—Pazopanib—kidney cancer	0.00234	0.00335	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—kidney cancer	0.00233	0.00333	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—CTNNB1—kidney cancer	0.00233	0.0203	CbGpPWpGaD
Fluocinonide—Headache—Pazopanib—kidney cancer	0.00233	0.00333	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—kidney cancer	0.00231	0.0033	CcSEcCtD
Fluocinonide—Pain—Sorafenib—kidney cancer	0.00218	0.00312	CcSEcCtD
Fluocinonide—Hypersensitivity—Vinblastine—kidney cancer	0.00217	0.0031	CcSEcCtD
Fluocinonide—Hypersensitivity—Everolimus—kidney cancer	0.00216	0.00309	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.00216	0.0188	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Capecitabine—kidney cancer	0.00214	0.00307	CcSEcCtD
Fluocinonide—Pain—Sunitinib—kidney cancer	0.0021	0.003	CcSEcCtD
Fluocinonide—Immune system disorder—Paclitaxel—kidney cancer	0.00209	0.00299	CcSEcCtD
Fluocinonide—Pruritus—Everolimus—kidney cancer	0.00208	0.00297	CcSEcCtD
Fluocinonide—Infection—Vincristine—kidney cancer	0.00206	0.00295	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00204	0.00291	CcSEcCtD
Fluocinonide—Nervous system disorder—Vincristine—kidney cancer	0.00203	0.00291	CcSEcCtD
Fluocinonide—Erythema—Paclitaxel—kidney cancer	0.00202	0.00289	CcSEcCtD
Fluocinonide—Triamcinolone—BCHE—kidney cancer	0.00201	0.0852	CrCbGaD
Fluocinonide—Pruritus—Erlotinib—kidney cancer	0.002	0.00287	CcSEcCtD
Fluocinonide—Pain—Dactinomycin—kidney cancer	0.00198	0.00284	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.00198	0.0173	CbGpPWpGaD
Fluocinonide—Infection—Gemcitabine—kidney cancer	0.00195	0.0028	CcSEcCtD
Fluocinonide—Dizziness—Vinblastine—kidney cancer	0.00195	0.00279	CcSEcCtD
Fluocinonide—Dizziness—Everolimus—kidney cancer	0.00194	0.00278	CcSEcCtD
Fluocinonide—Nervous system disorder—Gemcitabine—kidney cancer	0.00193	0.00276	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—FOSL1—kidney cancer	0.00191	0.0166	CbGpPWpGaD
Fluocinonide—Skin disorder—Gemcitabine—kidney cancer	0.00191	0.00273	CcSEcCtD
Fluocinonide—Clobetasol propionate—CYP1A1—kidney cancer	0.00189	0.0799	CrCbGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—kidney cancer	0.00189	0.0164	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Sorafenib—kidney cancer	0.00188	0.00268	CcSEcCtD
Fluocinonide—Dizziness—Erlotinib—kidney cancer	0.00187	0.00268	CcSEcCtD
Fluocinonide—Rash—Everolimus—kidney cancer	0.00185	0.00265	CcSEcCtD
Fluocinonide—Dermatitis—Everolimus—kidney cancer	0.00185	0.00264	CcSEcCtD
Fluocinonide—Headache—Vinblastine—kidney cancer	0.00185	0.00264	CcSEcCtD
Fluocinonide—Headache—Everolimus—kidney cancer	0.00184	0.00263	CcSEcCtD
Fluocinonide—Hypersensitivity—Sunitinib—kidney cancer	0.00181	0.00258	CcSEcCtD
Fluocinonide—Pruritus—Sorafenib—kidney cancer	0.0018	0.00258	CcSEcCtD
Fluocinonide—Rash—Erlotinib—kidney cancer	0.00179	0.00255	CcSEcCtD
Fluocinonide—Dermatitis—Erlotinib—kidney cancer	0.00178	0.00255	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.00178	0.0155	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.00178	0.0155	CbGpPWpGaD
Fluocinonide—Headache—Erlotinib—kidney cancer	0.00177	0.00254	CcSEcCtD
Fluocinonide—Pain—Vincristine—kidney cancer	0.00177	0.00254	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—OR4C13—kidney cancer	0.00176	0.0154	CbGpPWpGaD
Fluocinonide—Pruritus—Sunitinib—kidney cancer	0.00173	0.00248	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—BMP7—kidney cancer	0.00173	0.015	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—HNF1B—kidney cancer	0.00173	0.015	CbGpPWpGaD
Fluocinonide—Immune system disorder—Capecitabine—kidney cancer	0.00172	0.00246	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—kidney cancer	0.00171	0.00245	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00171	0.00244	CcSEcCtD
Fluocinonide—Dizziness—Sorafenib—kidney cancer	0.00168	0.00241	CcSEcCtD
Fluocinonide—Pain—Gemcitabine—kidney cancer	0.00168	0.00241	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	0.00167	0.0145	CbGpPWpGaD
Fluocinonide—Erythema—Capecitabine—kidney cancer	0.00166	0.00237	CcSEcCtD
Fluocinonide—Infection—Paclitaxel—kidney cancer	0.00164	0.00234	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—kidney cancer	0.00162	0.00232	CcSEcCtD
Fluocinonide—Dizziness—Sunitinib—kidney cancer	0.00162	0.00232	CcSEcCtD
Fluocinonide—Nervous system disorder—Paclitaxel—kidney cancer	0.00161	0.00231	CcSEcCtD
Fluocinonide—Rash—Sorafenib—kidney cancer	0.00161	0.0023	CcSEcCtD
Fluocinonide—Dermatitis—Sorafenib—kidney cancer	0.0016	0.0023	CcSEcCtD
Fluocinonide—Skin disorder—Paclitaxel—kidney cancer	0.0016	0.00229	CcSEcCtD
Fluocinonide—Headache—Sorafenib—kidney cancer	0.0016	0.00228	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—kidney cancer	0.00158	0.00227	CcSEcCtD
Fluocinonide—Rash—Sunitinib—kidney cancer	0.00155	0.00221	CcSEcCtD
Fluocinonide—Dermatitis—Sunitinib—kidney cancer	0.00154	0.00221	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—kidney cancer	0.00154	0.0134	CbGpPWpGaD
Fluocinonide—Headache—Sunitinib—kidney cancer	0.00154	0.0022	CcSEcCtD
Fluocinonide—Hypersensitivity—Vincristine—kidney cancer	0.00153	0.00219	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUND—kidney cancer	0.00148	0.0128	CbGpPWpGaD
Fluocinonide—Rash—Dactinomycin—kidney cancer	0.00146	0.00209	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	0.00146	0.0127	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	0.00145	0.0126	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	0.00142	0.0123	CbGpPWpGaD
Fluocinonide—Pain—Paclitaxel—kidney cancer	0.00141	0.00201	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.0014	0.002	CcSEcCtD
Fluocinonide—Pruritus—Gemcitabine—kidney cancer	0.00139	0.00199	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—kidney cancer	0.00138	0.00198	CcSEcCtD
Fluocinonide—Dizziness—Vincristine—kidney cancer	0.00137	0.00196	CcSEcCtD
Fluocinonide—Infection—Capecitabine—kidney cancer	0.00134	0.00192	CcSEcCtD
Fluocinonide—Nervous system disorder—Capecitabine—kidney cancer	0.00133	0.0019	CcSEcCtD
Fluocinonide—Skin disorder—Capecitabine—kidney cancer	0.00131	0.00188	CcSEcCtD
Fluocinonide—Rash—Vincristine—kidney cancer	0.00131	0.00187	CcSEcCtD
Fluocinonide—Dermatitis—Vincristine—kidney cancer	0.00131	0.00187	CcSEcCtD
Fluocinonide—Headache—Vincristine—kidney cancer	0.0013	0.00186	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—HNF1A—kidney cancer	0.00126	0.011	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—EPAS1—kidney cancer	0.00126	0.011	CbGpPWpGaD
Fluocinonide—Rash—Gemcitabine—kidney cancer	0.00124	0.00177	CcSEcCtD
Fluocinonide—Dermatitis—Gemcitabine—kidney cancer	0.00124	0.00177	CcSEcCtD
Fluocinonide—Headache—Gemcitabine—kidney cancer	0.00123	0.00176	CcSEcCtD
Fluocinonide—Hypersensitivity—Paclitaxel—kidney cancer	0.00121	0.00174	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—EGR1—kidney cancer	0.00117	0.0102	CbGpPWpGaD
Fluocinonide—Fluticasone furoate—ABCB1—kidney cancer	0.00117	0.0496	CrCbGaD
Fluocinonide—Pruritus—Paclitaxel—kidney cancer	0.00117	0.00167	CcSEcCtD
Fluocinonide—Pain—Capecitabine—kidney cancer	0.00116	0.00165	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—kidney cancer	0.00111	0.00158	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL13—kidney cancer	0.00109	0.0095	CbGpPWpGaD
Fluocinonide—Dizziness—Paclitaxel—kidney cancer	0.00109	0.00156	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—kidney cancer	0.00107	0.00153	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—OR4C13—kidney cancer	0.00104	0.00907	CbGpPWpGaD
Fluocinonide—Rash—Paclitaxel—kidney cancer	0.00104	0.00149	CcSEcCtD
Fluocinonide—Dermatitis—Paclitaxel—kidney cancer	0.00104	0.00148	CcSEcCtD
Fluocinonide—Headache—Paclitaxel—kidney cancer	0.00103	0.00148	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	0.00102	0.00888	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—ANXA1—kidney cancer	0.00102	0.00885	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUNB—kidney cancer	0.001	0.00874	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Capecitabine—kidney cancer	0.000996	0.00142	CcSEcCtD
Fluocinonide—Pruritus—Capecitabine—kidney cancer	0.000956	0.00137	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—EGR1—kidney cancer	0.000939	0.00817	CbGpPWpGaD
Fluocinonide—Methylprednisolone—ABCB1—kidney cancer	0.000935	0.0396	CrCbGaD
Fluocinonide—Triamcinolone—PTGS2—kidney cancer	0.000927	0.0393	CrCbGaD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—kidney cancer	0.000924	0.00804	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000902	0.00129	CcSEcCtD
Fluocinonide—Dizziness—Capecitabine—kidney cancer	0.000894	0.00128	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—LATS1—kidney cancer	0.000886	0.00771	CbGpPWpGaD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—kidney cancer	0.00088	0.00765	CbGpPWpGaD
Fluocinonide—Infection—Doxorubicin—kidney cancer	0.000865	0.00124	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—kidney cancer	0.000854	0.00122	CcSEcCtD
Fluocinonide—Rash—Capecitabine—kidney cancer	0.000852	0.00122	CcSEcCtD
Fluocinonide—Dermatitis—Capecitabine—kidney cancer	0.000851	0.00122	CcSEcCtD
Fluocinonide—Headache—Capecitabine—kidney cancer	0.000847	0.00121	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—kidney cancer	0.000846	0.00121	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—EGR1—kidney cancer	0.000827	0.0072	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	0.000801	0.00697	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	0.000792	0.0069	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—HIF1A—kidney cancer	0.000792	0.00689	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.000777	0.00676	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	0.000775	0.00674	CbGpPWpGaD
Fluocinonide—Betamethasone—PTGS2—kidney cancer	0.000759	0.0322	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—AMER1—kidney cancer	0.000753	0.00656	CbGpPWpGaD
Fluocinonide—Pain—Doxorubicin—kidney cancer	0.000745	0.00107	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	0.000734	0.00639	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKAP13—kidney cancer	0.000733	0.00637	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—kidney cancer	0.000727	0.00633	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP1A1—kidney cancer	0.000707	0.0299	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	0.0007	0.00609	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	0.000699	0.00608	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	0.000693	0.00603	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	0.000676	0.00588	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—HIF1A—kidney cancer	0.000653	0.00568	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL13—kidney cancer	0.000653	0.00568	CbGpPWpGaD
Fluocinonide—Betamethasone—ABCB1—kidney cancer	0.000646	0.0273	CrCbGaD
Fluocinonide—Hypersensitivity—Doxorubicin—kidney cancer	0.000642	0.000918	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—GPC3—kidney cancer	0.000631	0.00549	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CER1—kidney cancer	0.000631	0.00549	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ITPR2—kidney cancer	0.000623	0.00542	CbGpPWpGaD
Fluocinonide—Pruritus—Doxorubicin—kidney cancer	0.000616	0.000882	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	0.00061	0.00531	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—APC—kidney cancer	0.000589	0.00513	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	0.000577	0.00502	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—kidney cancer	0.000576	0.000824	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	0.000562	0.00489	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	0.000549	0.00478	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—kidney cancer	0.000549	0.000786	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—kidney cancer	0.000549	0.000785	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—kidney cancer	0.000546	0.000781	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—SFRP2—kidney cancer	0.000537	0.00467	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ANXA1—kidney cancer	0.000522	0.00454	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	0.000519	0.00451	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—POMC—kidney cancer	0.000498	0.00434	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.000495	0.0043	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—JUN—kidney cancer	0.000492	0.00428	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—kidney cancer	0.000483	0.0042	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	0.000477	0.00415	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—kidney cancer	0.000467	0.00407	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	0.000461	0.00401	CbGpPWpGaD
Fluocinonide—Dexamethasone—PTGS2—kidney cancer	0.000442	0.0187	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—AKAP13—kidney cancer	0.000433	0.00377	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP2—kidney cancer	0.000433	0.00377	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN1B—kidney cancer	0.000414	0.0036	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—kidney cancer	0.000405	0.00352	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HARS—kidney cancer	0.000405	0.00352	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—CTNNB1—kidney cancer	0.0004	0.00348	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—HIF1A—kidney cancer	0.000398	0.00346	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—RELA—kidney cancer	0.000396	0.00345	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GRB7—kidney cancer	0.000396	0.00344	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCND1—kidney cancer	0.000395	0.00344	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUN—kidney cancer	0.000394	0.00343	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CTNNB1—kidney cancer	0.000391	0.0034	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—kidney cancer	0.000381	0.00332	CbGpPWpGaD
Fluocinonide—Dexamethasone—ABCB1—kidney cancer	0.000376	0.0159	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—ITPR2—kidney cancer	0.000368	0.0032	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—kidney cancer	0.000357	0.00311	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—kidney cancer	0.000351	0.00305	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—kidney cancer	0.000347	0.00302	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF5B—kidney cancer	0.000344	0.003	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.000344	0.00299	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CTNNA1—kidney cancer	0.000334	0.0029	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EIF4EBP1—kidney cancer	0.000332	0.00289	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HSPB1—kidney cancer	0.000332	0.00289	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—kidney cancer	0.000317	0.00276	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PSMD7—kidney cancer	0.000308	0.00268	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TSC1—kidney cancer	0.000308	0.00268	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ANXA1—kidney cancer	0.000308	0.00268	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FLT1—kidney cancer	0.000299	0.0026	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—kidney cancer	0.000287	0.0025	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—kidney cancer	0.000282	0.00245	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PAK1—kidney cancer	0.000277	0.00241	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUNB—kidney cancer	0.000277	0.00241	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—kidney cancer	0.000273	0.00238	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—kidney cancer	0.00026	0.00226	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—POMC—kidney cancer	0.000256	0.00223	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CTNNB1—kidney cancer	0.000238	0.00207	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—kidney cancer	0.000229	0.00199	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF2—kidney cancer	0.000226	0.00197	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN2B—kidney cancer	0.000225	0.00196	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—JUNB—kidney cancer	0.000223	0.00194	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EEF2—kidney cancer	0.000222	0.00193	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1R—kidney cancer	0.000219	0.0019	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TET2—kidney cancer	0.000213	0.00185	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—RAF1—kidney cancer	0.000211	0.00183	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—JUN—kidney cancer	0.000208	0.00181	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.000206	0.00179	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TCEB1—kidney cancer	0.000195	0.00169	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—TCEB2—kidney cancer	0.000195	0.00169	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—kidney cancer	0.000189	0.00164	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CDKN2B—kidney cancer	0.000182	0.00158	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.000181	0.00158	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HIF1A—kidney cancer	0.00018	0.00157	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TSC2—kidney cancer	0.00018	0.00156	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KDR—kidney cancer	0.000172	0.0015	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KIT—kidney cancer	0.000159	0.00138	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APC—kidney cancer	0.000159	0.00138	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RPL14—kidney cancer	0.000158	0.00138	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAPK3—kidney cancer	0.000152	0.00132	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—POMC—kidney cancer	0.000151	0.00131	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—BRAF—kidney cancer	0.000149	0.0013	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAPK1—kidney cancer	0.000145	0.00126	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—kidney cancer	0.000137	0.00119	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF4EBP1—kidney cancer	0.000129	0.00112	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HSPB1—kidney cancer	0.000129	0.00112	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CA—kidney cancer	0.000125	0.00109	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RAF1—kidney cancer	0.000125	0.00108	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RELA—kidney cancer	0.000124	0.00108	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—kidney cancer	0.000123	0.00107	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MTOR—kidney cancer	0.000122	0.00106	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PSMD7—kidney cancer	0.00012	0.00104	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1B—kidney cancer	0.000114	0.000993	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—kidney cancer	0.000112	0.000972	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCND1—kidney cancer	0.000109	0.000947	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUN—kidney cancer	0.000109	0.000945	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CTNNB1—kidney cancer	0.000108	0.000938	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—JUNB—kidney cancer	0.000108	0.000936	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—kidney cancer	0.000105	0.000914	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—kidney cancer	9.49e-05	0.000826	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAPK3—kidney cancer	8.98e-05	0.000781	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CDKN2B—kidney cancer	8.76e-05	0.000762	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—kidney cancer	8.73e-05	0.00076	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAPK1—kidney cancer	8.54e-05	0.000743	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—kidney cancer	8.07e-05	0.000702	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CA—kidney cancer	7.41e-05	0.000645	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—kidney cancer	7.17e-05	0.000624	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—kidney cancer	7.05e-05	0.000613	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MAPK3—kidney cancer	3.49e-05	0.000304	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—kidney cancer	3.39e-05	0.000295	CbGpPWpGaD
